Cita APA (7a ed.)
Zuluaga-Sanchez, S., Hess, L. M., Wolowacz, S. E., D’yachkova, Y., Hawe, E., Vickers, A. D., . . . Bertwistle, D. (2018, March 26). Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States. Sarcoma, 1-15.
Cita Chicago Style (17a ed.)
Zuluaga-Sanchez, Santiago, Lisa M. Hess, Sorrel E. Wolowacz, Yulia D’yachkova, Emma Hawe, Adrian D. Vickers, James A. Kaye, y David Bertwistle. "Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States." Sarcoma 26 Mar. 2018: 1-15.
Cita MLA (9a ed.)
Zuluaga-Sanchez, Santiago, et al. "Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States." Sarcoma, 26 Mar. 2018, pp. 1-15.
Precaución: Estas citas no son 100% exactas.